Myriad Genetics Second Quarter 2026 Financial Earnings

7/30/2026 | 1:30 pm PDT / 4:30pm EDT

Webcast Link

Events & Presentations

  • Myriad Genetics Second Quarter 2026 Financial Earnings

    07/30/2026 | 1:30pm PDT / 4:30pm EDT

    Watch the webcast

  • Myriad Genetics First Quarter 2026 Financial Earnings

    05/05/2026 | 1:30pm PDT / 4:30pm EDT

    Watch the webcast View the document

  • Barclays 28th Annual Global Healthcare Conference

    03/11/2026 | 9:00pm PDT / 12:00am EDT

View all events

Financial Reports and Filings

Date Filing Title Downloads
06/23/2026 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
06/23/2026 8-K Report of unscheduled material events or corporate event RTF XLS PDF HTML XBRL
06/12/2026 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
06/12/2026 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
06/09/2026 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
06/08/2026 144 Filed by "insiders" prior intended sale of restricted stock. RTF XLS PDF HTML XBRL
06/05/2026 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
06/05/2026 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
06/05/2026 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
06/05/2026 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
View all filings

Latest News

Myriad Genetics to Release Second Quarter 2026 Financial Results on July 30, 2026 Thumbnail

Myriad Genetics to Release Second Quarter 2026 Financial Results on July 30, 2026

Jul 23, 2026 | Financial

Read more
Myriad Genetics Launches FirstGene® Multiple Prenatal Screen Thumbnail

Myriad Genetics Launches FirstGene® Multiple Prenatal Screen

Jul 21, 2026 | Products

Read more
New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad’s Prolaris® Biopsy Test in Localized Prostate Cancer Thumbnail

New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad’s Prolaris® Biopsy Test in Localized Prostate Cancer

Jul 02, 2026 | Products

Read more
View all news releases

2025 Corporate Responsibility Report

Our Corporate Responsibility strategy reflects our vision for the future of healthcare. Building on more than 30 years of scientific leadership, we aim to invest with discipline and purpose. We are delivering insights that help people take control of their health and empower healthcare providers to better detect, treat, and prevent disease.

Read our 2025 Corporate Responsibility report to learn how we are working to advance innovation, strengthen our impact, and support the creation of long-term value for patients, providers, employees, and the communities we serve.

Read the report
2025 Corporate Responsibility Report

2025 Corporate Responsibility Report

Our Corporate Responsibility strategy reflects our vision for the future of healthcare. Building on more than 30 years of scientific leadership, we aim to invest with discipline and purpose. We are delivering insights that help people take control of their health and empower healthcare providers to better detect, treat, and prevent disease.

Read our 2025 Corporate Responsibility report to learn how we are working to advance innovation, strengthen our impact, and support the creation of long-term value for patients, providers, employees, and the communities we serve.

Read the report
2025 Corporate Responsibility Report